齐拉西酮对精神分裂症患者心肌分子标志物的影响  

Effect of ziprasidone for myocardial molecular markers in patients with schizophrenia

作　　者：曾海深[1] 周少雄[1] 游青青[1] 黎文应 朱进才[1] 

机构地区：[1]佛山市第三人民医院检验科,广东佛山528000

出　　处：《医学检验与临床》2016年第3期24-25,3,共3页Medical Laboratory Science and Clinics

摘　　要：目的：本研究采用临床病例一对照及病例自身对照研究探讨伦非经典抗精神病药齐拉西酮对精神分裂症患者心肌分子标志物浓度水平的影响，并对此进行比较分析。方法：64例精神分裂症患者，经齐拉西酮治疗前后分别检测心肌损伤分子标志物（心肌肌红蛋白、心肌肌钙蛋白I）比较不同用药剂量患者心肌分子标志物水平的情况，分析服药剂量与心肌损伤的关系。结果：精神分裂症患者在随着齐拉西酮治疗剂量增大心肌损伤的分子标志物水平差异有统计学意义。（剂量为120ragBidP〈0．05）。结论：服用抗精神病药齐拉西酮剂量的大小可导致精神分裂症患者心肌分子标志物代谢异常。Objective ： This study adopted the clinical case-control and case self controlled to study Lunfei classical anti Antipsychotic drugs Ziprasidone＇ s effect on schizophrenia patients＇ molecular markers concentration of myocardial and the related comparative analysis. Methods： 64 cases of schizophrenia patients, before and after the treatment with ziprasidone were used to detect the molecular markers of myocardial injury （myocardial myoglobin and cardiac troponin I） with comparison of myocardial molecular marks of patients with different dosages and analysis of the relationship between dosage and myocardial injury.Results ： With the increase of ziprasidone dosage, schizophrenia patients＇ molecular marker of myocardial injury varies, which has statistical significance. （Dosage is 120mg Bid P〈0.05）. Conclusions ： How much dosage of antipsychotic drugs ziprasidone is taken would lead to metabolite abnormalities of schizophrenia patients＇ molecular markers of myocardial.

关 键 词：精神分裂症 齐拉西酮 心肌分子标志物 

分 类 号：R749.3[医药卫生—神经病学与精神病学]